18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: HER2-positive Breast Cancer
Interventions: DRUG: Pyrotinib
Sponsor: Biyun Wang, MD